Related Experiment Video
Updated: Jun 12, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid-lowering effects of gefarnate in statin-treated patients with residual hypertriglyceridemia: a randomized
Jing Shi1, Ming-Lu Xu1, Mei-Jiao He1
1Department of Cardiology, the First Affiliated Hospital, Harbin Medical University, Harbin, China.
Insights
Gefarnate, an anti-ulcer drug, significantly reduced triglyceride and increased HDL-C levels in coronary artery disease (CAD) patients on statin therapy. This suggests gefarnate offers dual benefits for CAD management.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipid Metabolism
Background:
- Coronary artery disease (CAD) management faces challenges including aspirin-induced gastrointestinal injury and residual cardiovascular risk despite statin treatment.
- Geraniol acetate (Gefarnate), an anti-ulcer medication, has shown potential in modulating lipid metabolism pathways.
- Residual hypertriglyceridemia in statin-treated CAD patients represents a persistent cardiovascular risk factor.
Purpose of the Study:
- To evaluate the lipid-lowering efficacy of gefarnate when added to statin therapy in CAD patients with residual hypertriglyceridemia.
- To assess the impact of gefarnate on plasma triglyceride, HDL-C, LDL-C, and total cholesterol levels.
Main Methods:
- A prospective, open-label, randomized controlled trial involving 69 statin-treated CAD patients with residual hypertriglyceridemia.
- Participants were randomized to receive either gefarnate (100 mg three times daily) plus statin or statin alone for one month.
- Plasma lipid profiles (triglyceride, HDL-C, LDL-C, total cholesterol) were measured at baseline and after the one-month treatment period.
Main Results:
- Gefarnate treatment significantly reduced triglyceride levels (2.64 to 2.12 mmol/L, P=0.0018) and increased HDL-C levels (0.97 to 1.17 mmol/L, P=0.0228).
- Compared to statin alone, gefarnate addition significantly lowered triglyceride levels (P=0.0148) and increased HDL-C levels (P=0.0307).
- While LDL-C and total cholesterol showed a trend towards decrease, these changes were not statistically significant.
Conclusions:
- Adding gefarnate to statin therapy significantly improves lipid profiles by reducing triglycerides and increasing HDL-C in CAD patients with residual hypertriglyceridemia.
- Gefarnate demonstrates potential dual benefits for CAD patients, addressing both lipid management and potential gastrointestinal protection.
- Further research is warranted to explore the long-term cardiovascular outcomes and gastroprotective effects of gefarnate in this patient population.
Background:
The prevention of coronary artery disease (CAD) faces dual challenges: the aspirin-induced gastrointestinal injury, and the residual cardiovascular risk after statin treatment. Geraniol acetate (Gefarnate) is an anti-ulcer drug. It was reported that geraniol might participate in lipid metabolism through a variety of pathways. The aim of this study was to assess the lipid-lowering effects of gefarnate in statin-treated CAD patients with residual hypertriglyceridemia.
Methods:
In this prospective, open-label, randomized, controlled trial, 69 statin-treated CAD patients with residual hypertriglyceridemia were randomly assigned to gefarnate group and control group, received gefarnate (100 mg/3 times a day) combined with statin and statin alone, respectively. At baseline and after one-month treatment, the levels of plasma triglyceride, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol were tested.
Results:
After one-month gefarnate treatment, triglyceride level was significantly lowered from 2.64 mmol/L to 2.12 mmol/L (P = 0.0018), LDL-C level lowered from 2.7 mmol/L to 2.37 mmol/L (P = 0.0004), HDL-C level increased from 0.97 mmol/L to 1.17 mmol/L (P = 0.0228). Based on statin therapy, gefarnate could significantly reduce the plasma triglyceride level (P = 0.0148) and increase the plasma HDL-C level (P = 0.0307). Although the LDL-C and total cholesterol levels tended to decrease, there was no statistically significant difference.
Conclusions:
The addition of gefarnate to statin reduced triglyceride level and increased HDL-C level to a significant extent compared to statin alone in CAD patients with residual hypertriglyceridemia. This suggested that gefarnate might provide the dual benefits of preventing gastrointestinal injury and lipid lowering in CAD patients.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
10:56A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
01:23Dipeptidyl Peptidase 4 Inhibitors